- Home
- / Lumos Pharma
Lumos Pharma
Stock Price
$4.4
2024-10-29
Market Capitalization
$35.5 M
2024-10-29
Revenue
$2.1 M
FY, 2023
Lumos Pharma Summary
Company Summary
- Overview
- Lumos Pharma is a biopharmaceutical company developing therapeutics for rare diseases. It provides LUM-201, an orally administered small molecule that promotes the secretion (secretagogue) of growth hormone from the pituitary gland. The company was formed as a result of a merger of Lumos Pharma with NewLink Genetics.
- Type
- Public
- Status
- Active
- Founded
- 2020
- HQ
- Austin, TX, US | view all locations
- Website
- https://lumos-pharma.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Brad Powers, General Counsel
Lori Lawley, Senior Vice President, Finance and Corporate Controller
Thomas A. Raffin, Director
LocationsView all
2 locations detected
Austin, TX HQ
United States
4200 Marathon Blvd #200
Ames, IA
United States
Research Park 5, 2503 S Loop Dr
Lumos Pharma Financials
Summary Financials
- Revenue (Q3, 2024)
- $726.0K
- Net income (Q3, 2024)
- ($7.5M)
- Cash (Q3, 2024)
- $13.5M
- EBIT (Q3, 2024)
- ($7.6M)
- Enterprise value
- $22.2M